Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oesophageal cancer

Novartis building

Novartis enters PD-1 race via CoStim acquisition

Expands presence in cancer immunotherapies

- PMLiVE

Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte

Sees combination potential for cancer prospect

- PMLiVE

Debunking cancer myths

World Cancer Day seeks to challenge preconceptions

- PMLiVE

Treatment alone will not tackle cancer epidemic, says WHO

Burden will be highest in developing countries

- PMLiVE

Servier expands breast cancer partnership

Will build on deal with French cancer research centre Curie-Cancer

- PMLiVE

Medigene buys cancer vaccine start-up

Acquires Trianta to boost immuno-oncology business

- PMLiVE

Blow to Pfizer as dacomitinib fails in lung cancer trials

Unable to demonstrate improved survival in patients

- PMLiVE

Merck shares jump on melanoma drug filing

MK-3475 could be approved by end of 2014

- PMLiVE

Novartis cancer chief Hoppenot leaves for top job at Incyte

He ends 10-year spell at Swiss pharma giant

AZ agrees cancer alliance with Immunocore

Medimmune subsidiary will work with biotech on encouraging patient's immune system to tackle tumours

- PMLiVE

AstraZeneca expands personalised drug partnership with Horizon

Companies will research drug targets for targeted cancer treatments

- PMLiVE

The oncology market in Canada

Ten per cent is not enough - simple estimates of the Canadian oncology market overlook a complex picture

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links